Study #2024-0113
A multicenter, open-label, phase II study to evaluate the efficacy and safety of Sutetinib maleate capsule in locally advanced or metastatic NSCLC (uncommon EGFR mutations only)
MD Anderson Study Status
Enrolling
Treatment Agent
Sutetinib Maleate Capsule
Description
The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non-small Cell Lung Cancer
Study phase:
Phase II
Physician name:
Xiuning Le
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-855-319-9556
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.